SCHEMBL6760520

SCHEMBL6760520

O=C(OC[C@H]1O[C@@H](n2ccc(-n3cncn3)nc2=O)[C@H](OC(=O)c2ccccc2)[C@@H]1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
MEN1 O00255 1/20 0.54
USP2 O75604 1/20 0.54
KMT2A Q03164 1/20 0.54
GAPDH P04406 2/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HRAS P01112 1/20 0.42
P2RX3 P56373 1/20 0.42
P2RX4 Q99571 1/20 0.42
P2RX2 Q9UBL9 1/20 0.42
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.37
LMNA P02545 1/20 0.37
P2RY6 Q15077 2/20 0.37
P2RY14 Q15391 2/20 0.37
NT5E P21589 1/20 0.37
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6760519 1.00 POLB (0.54) POLBMEN1USP2KMT2AGAPDH
SCHEMBL10459827 1.00 POLB (0.54) POLBMEN1USP2KMT2AGAPDH
SCHEMBL21055674 0.84 MEN1 (0.36) POLBMEN1USP2KMT2AGAPDH
SCHEMBL21345593 0.84 MEN1 (0.36) POLBMEN1USP2KMT2AGAPDH
SCHEMBL18870806 0.84 MEN1 (0.51) POLBMEN1USP2KMT2AGAPDH
SCHEMBL15810809 0.84 MEN1 (0.51) POLBMEN1USP2KMT2AGAPDH
SCHEMBL18852588 0.83 MEN1 (0.50) POLBMEN1USP2KMT2AGAPDH
SCHEMBL15810798 0.83 MEN1 (0.50) POLBMEN1USP2KMT2AGAPDH
SCHEMBL14011209 0.81 MEN1 (0.59) POLBMEN1USP2KMT2AGAPDH
SCHEMBL7706282 0.81 POLB (0.59) POLBMEN1USP2KMT2AGAPDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US disclosed
WO-2002018404-A9 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C HOFFMANN LA ROCHE (CH) 2003-10-02 WO disclosed
EP-1315736-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 EP disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US disclosed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 POLB 690/4885MEN1 4883/4885USP2 3286/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 POLB 690/4885MEN1 4883/4885USP2 3286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.